Peritoneal Metastases in Stage II-III Colon Cancer Represent a Blind Spot for Circulating Tumor DNA Surveillance.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 42265516.
- Also identified by DOI 10.1245/s10434-026-19903-8.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
While circulating tumor DNA (ctDNA) may guide adjuvant therapy in stage II-III colon cancer, detection largely hinges on systemic tumor shedding. In a secondary analysis of three prospective ctDNA studies, peritoneal metastases occurred in up to 9.4% of patients, were predominantly isolated, and were enriched among ctDNA-negative recurrences. Molecular and clinical data demonstrate reduced ctDNA levels in peritoneum-only disease, identifying a surveillance blind spot with direct implications for high-risk patients.